The combination of basal insulin with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) displayed the lowest GV and hypoglycemia in patients with T2DM, which might contribute to a reduction of cardiovascular outcome [115]. The gene discussed is GLP1R; the disease is Hypoglycemia.